Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome

secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial

Alfred Callahan, Pierre Amarenco, Larry B Goldstein, Henrik Sillesen, Mike Messig, Gregory P Samsa, Irfan Altafullah, Lucy Y Ledbetter, Mary J MacLeod, Russell Scott, Michael Hennerici, Justin A Zivin, K Michael A Welch, SPARCL Investigators

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

To perform a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial, which tested the effect of treatment with atorvastatin in reducing stroke in subjects with a recent stroke or transient ischemic attack, to explore the effects of treatment in subjects with type 2 diabetes mellitus or metabolic syndrome (MetS).
Original languageEnglish
Pages (from-to)1245-1251
Number of pages7
JournalArchives of Neurology
Volume68
Issue number10
DOIs
Publication statusPublished - 2011

Fingerprint

Transient Ischemic Attack
Type 2 Diabetes Mellitus
Stroke
Myocardial Infarction
Cholesterol
Therapeutics
Secondary Analysis
Syndrome
Attack
Type 2 Diabetes

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Cardiovascular Physiological Processes
  • Cholesterol
  • Confidence Intervals
  • Diabetes Mellitus, Type 2
  • Female
  • Heptanoic Acids
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Ischemic Attack, Transient
  • Lipoproteins, HDL
  • Lipoproteins, LDL
  • Male
  • Metabolic Syndrome X
  • Middle Aged
  • Proportional Hazards Models
  • Pyrroles
  • Retrospective Studies
  • Risk Factors
  • Stroke
  • Triglycerides
  • Young Adult

Cite this

Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome : secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. / Callahan, Alfred; Amarenco, Pierre; Goldstein, Larry B; Sillesen, Henrik; Messig, Mike; Samsa, Gregory P; Altafullah, Irfan; Ledbetter, Lucy Y; MacLeod, Mary J; Scott, Russell; Hennerici, Michael; Zivin, Justin A; Welch, K Michael A; SPARCL Investigators.

In: Archives of Neurology, Vol. 68, No. 10, 2011, p. 1245-1251.

Research output: Contribution to journalArticle

Callahan, Alfred ; Amarenco, Pierre ; Goldstein, Larry B ; Sillesen, Henrik ; Messig, Mike ; Samsa, Gregory P ; Altafullah, Irfan ; Ledbetter, Lucy Y ; MacLeod, Mary J ; Scott, Russell ; Hennerici, Michael ; Zivin, Justin A ; Welch, K Michael A ; SPARCL Investigators. / Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome : secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. In: Archives of Neurology. 2011 ; Vol. 68, No. 10. pp. 1245-1251.
@article{0bb61f0f753f4959b60f1a617cf881e2,
title = "Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial",
abstract = "To perform a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial, which tested the effect of treatment with atorvastatin in reducing stroke in subjects with a recent stroke or transient ischemic attack, to explore the effects of treatment in subjects with type 2 diabetes mellitus or metabolic syndrome (MetS).",
keywords = "Adult, Aged, Aged, 80 and over, Cardiovascular Physiological Processes, Cholesterol, Confidence Intervals, Diabetes Mellitus, Type 2, Female, Heptanoic Acids, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Ischemic Attack, Transient, Lipoproteins, HDL, Lipoproteins, LDL, Male, Metabolic Syndrome X, Middle Aged, Proportional Hazards Models, Pyrroles, Retrospective Studies, Risk Factors, Stroke, Triglycerides, Young Adult",
author = "Alfred Callahan and Pierre Amarenco and Goldstein, {Larry B} and Henrik Sillesen and Mike Messig and Samsa, {Gregory P} and Irfan Altafullah and Ledbetter, {Lucy Y} and MacLeod, {Mary J} and Russell Scott and Michael Hennerici and Zivin, {Justin A} and Welch, {K Michael A} and {SPARCL Investigators}",
year = "2011",
doi = "10.1001/archneurol.2011.146",
language = "English",
volume = "68",
pages = "1245--1251",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome

T2 - secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial

AU - Callahan, Alfred

AU - Amarenco, Pierre

AU - Goldstein, Larry B

AU - Sillesen, Henrik

AU - Messig, Mike

AU - Samsa, Gregory P

AU - Altafullah, Irfan

AU - Ledbetter, Lucy Y

AU - MacLeod, Mary J

AU - Scott, Russell

AU - Hennerici, Michael

AU - Zivin, Justin A

AU - Welch, K Michael A

AU - SPARCL Investigators

PY - 2011

Y1 - 2011

N2 - To perform a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial, which tested the effect of treatment with atorvastatin in reducing stroke in subjects with a recent stroke or transient ischemic attack, to explore the effects of treatment in subjects with type 2 diabetes mellitus or metabolic syndrome (MetS).

AB - To perform a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial, which tested the effect of treatment with atorvastatin in reducing stroke in subjects with a recent stroke or transient ischemic attack, to explore the effects of treatment in subjects with type 2 diabetes mellitus or metabolic syndrome (MetS).

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Cardiovascular Physiological Processes

KW - Cholesterol

KW - Confidence Intervals

KW - Diabetes Mellitus, Type 2

KW - Female

KW - Heptanoic Acids

KW - Humans

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors

KW - Ischemic Attack, Transient

KW - Lipoproteins, HDL

KW - Lipoproteins, LDL

KW - Male

KW - Metabolic Syndrome X

KW - Middle Aged

KW - Proportional Hazards Models

KW - Pyrroles

KW - Retrospective Studies

KW - Risk Factors

KW - Stroke

KW - Triglycerides

KW - Young Adult

U2 - 10.1001/archneurol.2011.146

DO - 10.1001/archneurol.2011.146

M3 - Article

VL - 68

SP - 1245

EP - 1251

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 10

ER -